Therapeutic subgroup
L04 – IMMUNSUPPRESSIVA
- Anatomical main group L: ANTINEOPLASTISCHE UND IMMUNMODULIERENDE MITTEL
118Decisions
215Patient groups
Added benefit by patient group
- Considerable14
- Minor22
- Non-quantifiable16
- Not proven163
Subgroups
- L04A IMMUNSUPPRESSIVA 118 decisions
Decisions, newest first
- 2026-09-03UpliznaInebilizumabNot proven: 2 of 2 patient groups
- 2026-09-03UpliznaInebilizumabNon-quantifiable
- 2026-08-20TepezzaTeprotumumabNot proven: 3 of 3 patient groups
- 2026-08-06AspaveliPegcetacoplanNon-quantifiable
- 2026-08-06AspaveliPegcetacoplanNon-quantifiable
- 2026-06-18TremfyaGuselkumabNot proven
- 2026-06-18ImaavyNipocalimabNot proven: 4 of 4 patient groups
- 2026-06-04FabhaltaIptacopanNot proven
- 2026-06-04FabhaltaIptacopanNot proven: 2 of 2 patient groups
- 2026-03-19TaltzIxekizumabNot proven
- 2026-03-19TaltzIxekizumabNot proven
- 2026-03-05TavneosAvacopanNot proven
- 2026-01-22VyvgartEfgartigimod alfaNot proven
- 2025-11-20TremfyaGuselkumabNot proven: 2 of 2 patient groups
- 2025-11-20TremfyaGuselkumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-11-06RinvoqUpadacitinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-09-04OmvohMirikizumabNot proven: 2 of 2 patient groups
- 2025-08-07KevzaraSarilumabNot proven: 2 of 2 patient groups
- 2025-08-07KevzaraSarilumabNot proven
- 2025-05-15OtezlaApremilastNot proven
- 2025-03-06PiaSkyCrovalimabNot proven: 2 of 2 patient groups
- 2025-02-20SkyriziRisankizumabNot proven: 2 of 2 patient groups
- 2024-11-22VoydeyaDanicopanNon-quantifiable
- 2024-11-22BimzelxBimekizumabNot proven
- 2024-11-22AspaveliPegcetacoplanNon-quantifiable
- 2024-10-02VelsipityEtrasimodNot proven: 2 of 2 patient groups
- 2024-09-19VyvgartEfgartigimod alfaNot proven
- 2024-08-15RystiggoRozanolixizumabConsiderable: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2024-08-15ZilbrysqZilucoplanNot proven
- 2024-08-01BriumviUblituximabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-05-02OlumiantBaricitinibNot proven
- 2024-05-02OlumiantBaricitinibNot proven: 2 of 2 patient groups
- 2024-05-02OlumiantBaricitinibNot proven: 3 of 3 patient groups
- 2024-05-02OlumiantBaricitinibNot proven: 2 of 2 patient groups
- 2024-03-21HyftorSirolimusNon-quantifiable
- 2024-01-18OmvohMirikizumabNot proven: 2 of 2 patient groups
- 2024-01-18TecfideraDimethylfumaratNot proven
- 2023-12-21BimzelxBimekizumabNot proven: 2 of 2 patient groups
- 2023-12-21BimzelxBimekizumabNot proven: 2 of 2 patient groups
- 2023-12-21BimzelxBimekizumabNot proven: 2 of 2 patient groups
- 2023-12-07UltomirisRavulizumabNot proven
- 2023-12-07CosentyxSecukinumabNot proven
- 2023-10-19RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2023-10-05SotyktuDeucravacitinibNot proven: 2 of 2 patient groups
- 2023-08-17LupkynisVoclosporinNot proven
- 2023-07-20SpevigoSpesolimabNot proven
- 2023-06-15EnjaymoSutimlimabMinor
- 2023-06-15SkyriziRisankizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-04-20UltomirisRavulizumabNot proven
- 2023-02-16RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2023-02-16RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2023-01-19UpliznaInebilizumabNot proven
- 2023-01-05CosentyxSecukinumabNot proven
- 2023-01-05CosentyxSecukinumabNot proven
- 2022-10-06SaphneloAnifrolumabNot proven
- 2022-09-15AspaveliPegcetacoplanNon-quantifiable
- 2022-09-01EntyvioVedolizumabNot proven
- 2022-08-04TavneosAvacopanMinor
- 2022-06-16ZeposiaOzanimodNot proven: 2 of 2 patient groups
- 2022-06-16XeljanzTofacitinibNot proven: 2 of 2 patient groups
- 2022-05-19PonvoryPonesimodMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-05-19SkyriziRisankizumabNot proven: 2 of 2 patient groups
- 2022-05-19JyselecaFilgotinibNot proven: 2 of 2 patient groups
- 2022-03-18UltomirisRavulizumabNot proven: 2 of 2 patient groups
- 2022-03-03XeljanzTofacitinibNot proven: 5 of 5 patient groups
- 2022-03-03BimzelxBimekizumabMinor: 2 of 2 patient groups
- 2022-02-17XeljanzTofacitinibNot proven: 6 of 6 patient groups
- 2022-02-17RinvoqUpadacitinibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-01-20AubagioTeriflunomidNot proven
- 2022-01-06EnspryngSatralizumabMinor
- 2021-12-02PonvoryPonesimodNot proven
- 2021-09-02IdefirixImlifidaseNon-quantifiable
- 2021-07-15RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2021-07-15RinvoqUpadacitinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-05-20TremfyaGuselkumabNot proven: 2 of 2 patient groups
- 2021-05-06OlumiantBaricitinibNot proven
- 2021-04-15JyselecaFilgotinibMinor: 1 of 6 patient groupsNot proven: 5 of 6 patient groups
- 2021-02-18CosentyxSecukinumabNot proven
- 2021-02-18CosentyxSecukinumabMinor
- 2021-02-18CosentyxSecukinumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-01-21TaltzIxekizumabNot proven
- 2021-01-21TaltzIxekizumabNot proven: 3 of 3 patient groups
- 2021-01-21UltomirisRavulizumabNot proven
- 2021-01-07ZeposiaOzanimodMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2020-11-05OtezlaApremilastNot proven
- 2020-08-20MayzentSiponimodNot proven: 2 of 2 patient groups
- 2020-07-16RinvoqUpadacitinibConsiderable: 1 of 7 patient groupsMinor: 1 of 7 patient groupsNot proven: 5 of 7 patient groups
- 2020-05-14BenlystaBelimumabNon-quantifiable
- 2020-02-06UltomirisRavulizumabNot proven: 2 of 2 patient groups
- 2019-12-05Imnovid PomalidomidNot proven
- 2019-11-22SkyriziRisankizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2019-06-20GilenyaFingolimodNon-quantifiable: 2 of 4 patient groupsNot proven: 2 of 4 patient groups
- 2019-05-02IlumetriTildrakizumabNot proven: 2 of 2 patient groups
- 2019-02-21XeljanzTofacitinibNot proven: 2 of 2 patient groups
- 2019-02-21XeljanzTofacitinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-11-22AlofiselDarvadstrocelNon-quantifiable
- 2018-08-16TaltzIxekizumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2018-08-02OcrevusOcrelizumabMinor: 2 of 3 patient groupsNot proven: 1 of 3 patient groups
- 2018-05-17TremfyaGuselkumabConsiderable: 2 of 2 patient groups
- 2018-05-17MavencladCladribinNot proven: 2 of 2 patient groups
- 2018-03-01KyntheumBrodalumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-02-15KevzaraSarilumabConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2017-09-21OlumiantBaricitinibNot proven: 4 of 4 patient groups
- 2017-08-17CosentyxSecukinumabConsiderable
- 2017-08-17TaltzIxekizumabConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2016-06-02CosentyxSecukinumabNot proven
- 2016-05-19GilenyaFingolimodNot proven: 2 of 2 patient groups
- 2016-03-17Imnovid PomalidomidConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-01-07NulojixBelataceptConsiderable
- 2015-11-27CosentyxSecukinumabConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2015-10-01GilenyaFingolimodMinor
- 2015-08-06OtezlaApremilastNot proven: 2 of 2 patient groups
- 2015-01-08EntyvioVedolizumabNot proven: 4 of 4 patient groups
- 2014-12-04SylvantSiltuximabNon-quantifiable
- 2014-10-16TecfideraDimethylfumaratNot proven
- 2014-03-20AubagioTeriflunomidNot proven
- 2012-08-02BenlystaBelimumabConsiderable
- 2012-03-15EsbrietPirfenidonNon-quantifiable
Data status: 2026-10-29